Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

University of Cologne

Overview

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Interventions

RituximabDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * lymphocyte predominant Hodgkin´s lymphoma (histologically proven) * clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h) * age 18 - 75 * WHO performance status 0-3 * normal organ function * written informed consent Exclusion Criteria: * classical Hodgkin´s lymphoma * composite lymphoma * leucocytes \< 3000/µl * thrombocytes \< 100.000/µl

Locations (1)

University of Cologne

Cologne, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.